**Transcend Vivoscope**

**1. Company Profile**

***1.1 Company Identification***

***1.2 Business Description***

***1.3 Technology and Products***

***1.4 Target Customers***

***1.5 Leadership & Governance***

***1.6 Milestones & Achievements***

***1.7 Strategic Positioning***

**2. Industry Analysis**

***2.1 Industry Definition and Scope***

Biomedical imaging focuses on multiphoton technologies for live-body detection, serving brain science, clinical, and other sectors.

***2.2 Industry Size and Growth***

The global brain science market will exceed $10B by 2024, with China’s high-end instrument sector growing driven by policies and demand.

***2.3 Competitive Landscape***

International players dominate traditional markets, while SuperVision’s exclusive miniature two-photon technology creates a unique moat.

***2.4 Drivers***

1. Technological Advancements: Miniature two/three-photon and AI-integrated technologies overcome deep-imaging and analysis challenges, driving research innovation.
2. Policy Support: China’s "Brain Project" (¥50B+ budget) and STAR Market policies prioritize hard-tech enterprises.
3. Demand Surge: Aging-driven clinical needs (e.g., noninvasive diagnostics) and global research papers (>450K) fuel instrument upgrades.

***2.5 Constraints***

1. Technical Frontiers: Multimodal fusion and super-resolution blood flow imaging face laser control and signal interference hurdles.
2. Scalability and Translation: Mass production requires cost-process optimization, while medical approvals extend clinical cycles to 2-3 years.

***2.6 Policy Environment***

Government policies favor domestic substitution, requiring SuperVision to maintain sci-tech compliance (R&D >40%, patent portfolio).

**3. Evaluation**

***3.1 Profit Forecast***

3.1.1 Revenue Forecast

3.1.2 Cost Forecast

3.1.3 Expense Forecast

3.1.4 Overall Profit Forecast

***3.2 Relative Valuation***

3.2.1 Select the Universe of Comparable Companies

3.2.2 Locate the Necessary Financial Information

3.2.3 Spread Key Statistics, Ratios, and Trading Multiples

3.2.4 Benchmark the Comparable Companies

3.2.5 Determine Valuation

***3.3 Precedent Transactions Analysis***

3.3.1 Select the Universe of Comparable Financing Round

3.3.2 Locate the Necessary Deal-Related Information

3.3.3 Spread Key Statistics, Ratios, and Trading Multiples

3.3.4 Benchmark the Comparable Financing Round

3.3.5 Determine Valuation

***DCF? Data Loss***

**4. Investment Strategy**

***4.1 Staged Investment Plan***

***4.2 Contracting***

***4.3 Investment Highlight?***

***4.4 Investment Risk?***

**5. Exit Plan**

***5.1 Optimal Exit Way — XXX (IPO or Acquisition or Trade-sale)***

Comparing and explaining why xxx is the optimal exit way.

***5.2 Part A. For XXX***

Details for Exit Way.

***5.3 Part B. For XXX***

***5.4 Part ... For XXX***